From 5th August we will begin to report PALB2 variants in addition to BRCA1 and BRCA2 when testing for suitability to prescribe Olaparib/Talazoparib for treatment of breast cancer (R444.1).
This change is a response to guidance issued by the UK Cancer Genetics Group / Cancer Variant Interpretation Group UK informed by real world feedback gathered by them. The change is intended to ensure detection of relevant high penetrance gene variants, while informing use of PARP inhibitor treatment, and helping to meet expected turnaround times.